Deoxynivalenol | 脱氧雪腐镰刀菌烯醇

MCE 国际站：Deoxynivalenol

中文名：脱氧雪腐镰刀菌烯醇

CAS：51481-10-8

品牌：MedChemExpress (MCE)

存储条件：Powder: -20°C, 3 years.In solvent: -80°C, 6 months; -20°C, 1 month.

生物活性：脱氧雪腐镰刀菌烯醇是单端孢霉烯属的一种真菌毒素，通过细胞旁通路通过紧密连接穿过肠粘膜。脱氧雪腐镰刀菌烯醇的转运不受 P-糖蛋白 (PgP) 或多药耐药相关蛋白 (MRP) 抑制剂的影响^[1]。

体外：Deoxynivalenol (0-2 μg/mL, 24 h) 会引发 Caco-2 细胞中丝裂原激活蛋白激酶 (MAPKs) Erk1/2、p38 和 SAPK/JNK 的磷酸化[1]。 Deoxynivalenol (100-4000 ng/mL, 24-72 h) 在 500-4000 ng/mL 剂量下孵育 48 小时和 72 小时后，会降低 IPEC-1 和 IPEC-J2 细胞的活力[2]。 Deoxynivalenol (0-4000 ng/mL, 24-72 h) 在 IPEC-1 和 IPEC-J2 细胞中，浓度为 200 ng/mL 时增加BrdU 的掺入，浓度为2000-4000 ng/mL时减少 BrdU 的掺入[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Deoxynivalenol (0-5 mg/kg, 灌胃, 每日一次, 14 天) 会以剂量相关的方式增加流涎过多的妊娠大鼠的数量[3]。 Deoxynivalenol (0-5 mg/kg, 灌胃, 每日一次, 14 天) 在 5 mg/kg 剂量下会导致大鼠胎儿胸骨发育异常[3]。 Deoxynivalenol (10-1000 mg/kg; 口服, 腹腔注射; 一次) 对 B6C3F1 小鼠的 LD50 值估计为 78 mg/kg (口服) 和 49 mg/kg (腹腔注射)[4]。 Deoxynivalenol (2-20 mg/kg, 口服, 每日一次, 4 周) 以剂量依赖性方式增加血浆浓度，并减少 B6C3F1 小鼠的体重增加[5]。 1.19 药代动力学分析[5] Route Dose (mg/kg) Plasma T1/2α (min) Plasma T1/2β (h) Liver T1/2α (min) Liver T1/2β (h) Kidney T1/2α (min) Kidney T1/2β (h) Spleen T1/2α (min) Spleen T1/2β (h) Heart T1/2α (min) Heart T1/2β (h) p.o. 25 20.4 11.8 22 19 47 20.9 29 9 41 12.3 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Pregnant rats[3] Dosage: 0-5 mg/kg Administration: i.g., daily, 14 days Result: Reduced feed consumption and mean body weight gain in the 5 mg/kg group . Reduced feed consumption in the 2.5 mg/kg group during 8-14 days. Decreased the number of viable fetuses at 5 mg/kg. Reduced fetal body weight and crown-rump length at 2.5 and 5 mg/kg. Increased the incidence of runts and the average number of fetuses per litter with internal anomalies at 2.5 and 5 mg/kg. Increased the incidence of misaligned and fused sternebrae at 5 mg/kg. Increased the ratios of liver-to-body-weight and kidneys-to-body-weight.

热销产品：Clarithromycin  | PAR-4 Agonist Peptide, amide (TFA)  | 2OH-BNPP1  | Pimozide  | Sintilimab  | ATP-polyamine-biotin  | TAPI-2  | Fmoc-Gly-Gly-Phe-OH  | Prim-O-glucosylcimifugin  | Glycine

研究领域：Others

作用靶点：Others

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

参考文献：[1]. Sergent T, et al. Deoxynivalenol transport across human intestinal Caco-2 cells and its effects on cellularmetabolism at realistic intestinal concentrations. Toxicol Lett. 2006 Jul 1;164(2):167-76.

[2]. Diesing AK, et al. Mycotoxin deoxynivalenol (DON) mediates biphasic cellular response in intestinal porcine epithelial cell lines IPEC-1 and IPEC-J2. Toxicol Lett. 2011 Jan 15;200(1-2):8-18. 

[3]. Collins TF, et al. Effects of deoxynivalenol (DON, vomitoxin) on in utero development in rats. Food Chem Toxicol. 2006 Jun;44(6):747-57.

[4]. Pestka JJ, et al. Immunochemical assessment of deoxynivalenol tissue distribution following oral exposure in the mouse. Toxicol Lett. 2008 May 5;178(2):83-7.[5]. Forsell JH, et al. Comparison of acute toxicities of deoxynivalenol (vomitoxin) and 15-acetyldeoxynivalenol in the B6C3F1 mouse. Food Chem Toxicol. 1987 Feb;25(2):155-62.